FDA allows Curis to resume testing cancer drugReuters(Reuters) – Curis Inc said the U.S. Food and Drug Administration allowed it to resume testing its experimental cancer drug, lifting a November order halting enrolment in an early-stage trial. The company’s shares jumped about 22 percent to $3.35 in trading …Curis Announces Removal of FDA Partial Clinical Hold on CUDC-427MarketWatchCuris Announces Presentation of Data for CUDC-907, CUDC-427 and Debio …GlobeNewswire (press release)all 4 news articles …Read Full Story
FDA allows Curis to resume testing cancer drug - Reuters
Real Estate of Cebu
